Back to Treatments

Treatment

Extended Half-Life (EHL) Recombinant Factor VIII

1
Conditions
2
Trials
8,000
Participants
65%
Average Safety

Condition Evidence

Hemophilia

2 trials · 8,000 participants

90% effectiveness · 65% safety
Extended Half-Life (EHL) Recombinant Factor VIII | DFDA